Personalis, Inc. (PSNL)
15.93
+0.03
(+0.19%)
USD |
NASDAQ |
Oct 15, 16:00
15.92
-0.01
(-0.06%)
After-Hours: 20:00
Personalis Research and Development Expense (Quarterly) : 16.34M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.34M |
| March 31, 2026 | 14.54M |
| December 31, 2025 | 13.07M |
| September 30, 2025 | 12.17M |
| June 30, 2025 | 12.38M |
| March 31, 2025 | 12.64M |
| December 31, 2024 | 11.49M |
| September 30, 2024 | 11.68M |
| June 30, 2024 | 12.96M |
| March 31, 2024 | 12.77M |
| December 31, 2023 | 13.61M |
| September 30, 2023 | 16.74M |
| June 30, 2023 | 17.85M |
| March 31, 2023 | 16.57M |
| December 31, 2022 | 16.57M |
| September 30, 2022 | 14.96M |
| June 30, 2022 | 16.29M |
| Date | Value |
|---|---|
| March 31, 2022 | 17.10M |
| December 31, 2021 | 14.51M |
| September 30, 2021 | 13.62M |
| June 30, 2021 | 11.69M |
| March 31, 2021 | 9.496M |
| December 31, 2020 | 8.52M |
| September 30, 2020 | 7.193M |
| June 30, 2020 | 6.465M |
| March 31, 2020 | 6.39M |
| December 31, 2019 | 7.373M |
| September 30, 2019 | 5.303M |
| June 30, 2019 | 4.497M |
| March 31, 2019 | 5.245M |
| December 31, 2018 | 4.281M |
| September 30, 2018 | 3.574M |
| June 30, 2018 | 3.50M |
| March 31, 2018 | 2.949M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tempus AI, Inc. | 96.57M |
| 10X Genomics, Inc. | 56.79M |
| Alamar Biosciences, Inc. (California) | 13.82M |
| Adaptive Biotechnologies Corp. | 18.30M |
| Champions Oncology, Inc. | 2.344M |